KeyBanc says recent announcements indicate that momentum is building at Lifecore (LFCR). The company on December 17 announced a technology transfer win with a new large multinational pharmaceutical customer, which followed a win with another large multinational that was announced on the last earnings call, the analyst tells investors in a research note. In addition, the firm points out that Lifecore was added to the Nasdaq Biotech Index on December 22, which could increase investor awareness. KeyBanc believes Lifecore’s outer year visibility is improving and that the company’s focus on fill/finish continues to have potential strategic value. The firm keeps a Sector Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 28
- Lifecore to be added to Nasdaq Biotechnology Index
- Lifecore signs CDMO master services agreement with pharma customer
- Cautious Hold Rating on Lifecore Biomedical Amid Operational Progress and Financial Risks
- Optimistic Outlook for Lifecore Biomedical: Strategic Growth and Financial Stability